drugset
drugset / Trial / NCT00918333

Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma

NCT00918333 ↗

Phase 1/2 Completed 124 enrolled Mayo Clinic National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase I/II trial studies the side effects and best dose of panobinostat and everolimus when given together and to see how well they work in treating patients with multiple myeloma, non-Hodgkin lymphoma, or Hodgkin lymphoma that has come back. Panobinostat and everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2009-06
Primary completion
2015-12-01
Completion
2019-07-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule — Oral
Subject Panobinostat Small molecule — Oral

Indications

B-cell adult acute lymphocytic leukemia Burkitt lymphoma Hodgkins lymphoma MALT lymphoma T-cell adult acute lymphocytic leukemia Waldenstrom macroglobulinemia adult T-cell leukemia/lymphoma anaplastic large cell lymphoma angioimmunoblastic T-cell lymphoma chronic lymphocytic leukemia/small lymphocytic lymphoma diffuse large B-cell lymphoma extranodal nasal NK/T cell lymphoma hepatosplenic T-cell lymphoma lymphoblastic lymphoma mantle cell lymphoma mycosis fungoides and variants nodal marginal zone B-cell lymphoma plasma cell myeloma post-transplant lymphoproliferative disease primary central nervous system lymphoma primary cutaneous T-cell non-Hodgkin lymphoma splenic marginal zone lymphoma